PFE · Full Picture

PFIZER INC — the full picture

Earnings window · 2026-07-14 to 2026-09-24 · anchored on the 10-Q report

One earnings window, everything merged: the filing, the call, press releases and news digests, folded into ranked threads.

What to look at first

  1. Capital Return Program · Buybacks & dividendsPriority 90
    -36.6% operating_income (realized); 4 sources (news, press_release, sec_filing, transcript); 2 forward row(s); quote_verified
    As of June 28, 2026, Pfizer's remaining share-purchase authorization was $3.3 billion, with no repurchases in the first six months of 2026.
  2. Acquisition / Partnership / Divestiture · M&A and divestituresPriority 89
    -4.0% operating_income; 4 sources (news, press_release, sec_filing, transcript); 11 forward row(s); structured_verified
    PFIZER INC said it has a remaining $6 to $7 billion available for bolt-on business development opportunities and that investors should expect opportunities in that size range.
  3. Revenue Performance and Mix · Revenue growth & mixPriority 88
    +20.3% revenue (realized); 4 sources (news, press_release, sec_filing, transcript); 3 forward row(s); structured_verified
    Pfizer reported quarterly earnings of $0.77 EPS and $15.03 billion in revenue, beating estimates.
  4. Guidance and Outlook · Guidance & outlookPriority 85
    +2.8% revenue; 4 sources (news, press_release, sec_filing, transcript); 9 forward row(s); quote_verified
    Pfizer expects full-year 2026 revenue to total $60.5 billion to $62.5 billion, compared with a previous outlook of $59.5 billion to $62.5 billion.
  5. Headcount / Restructuring · Restructuring & impairmentPriority 83
    +27.3% operating_income; 4 sources (news, press_release, sec_filing, transcript); 4 forward row(s); structured_verified
    Announces additional anticipated productivity enhancement savings of $2.5 billion expected to be realized from 2027 through 2029
  6. Patent Exclusivity Expiries · Intellectual propertyPriority 79
    -14.5% revenue; 2 sources (news, sec_filing); 1 forward row(s); quote_verified
    Trefis reported Pfizer faces $14 billion to $15 billion in annual revenue at risk from its patent cliff.
  7. Cost Realignment Program · UnclassifiedPriority 78
    +73.0% operating_income; 4 forward row(s); quote_verified
    Pfizer's Cost Realignment Program expansions are set to deliver $7.2 billion in net savings by 2026 and another $2.5 billion through 2029.
  8. Operating Expense Trends · Operating expenses (SG&A)Priority 78
    +66.2% operating_income; 3 sources (press_release, sec_filing, transcript); 7 forward row(s); structured_verified
    Pfizer now expects approximately $9.7 billion in total net savings from its productivity initiatives through 2029.
  9. COVID Product Demand Decline · Demand, orders & backlogPriority 77
    -5.7% revenue; 3 sources (news, press_release, transcript); 2 forward row(s); quote_verified
    Revised 2026 revenue expectation for COVID-19 products: down to approximately $4 billion from approximately $5 billion previously
  10. Gross Margin Drivers · Gross marginPriority 76
    -8.3% operating_income; 3 sources (press_release, sec_filing, transcript); 4 forward row(s); structured_verified
    Next phase of Manufacturing Optimization Program expected to deliver additional anticipated savings of approximately $1.5 billion through 2029 with one-time costs to achieve savings expected to be approximately $4.0 billion, ~60% non-cash and ~40% cash
  11. Intangible Asset Impairments · UnclassifiedPriority 76
    -28.8% net_income (realized); 2 sources (press_release, transcript); quote_verified
    Pfizer recorded $4.3 billion in noncash intangible asset impairments in Q2 2026 related primarily to SV and removal of revenue projection for Oxbryta.
  12. Strategic Cost Savings · UnclassifiedPriority 76
    +32.3% operating_income; 1 forward row(s); quote_verified
    Pfizer's operational efficiency programs target $9.7B in cost savings through 2029.

Threads by pillar

Revenue & Demand Priority 94 · 10 threads

Costs & Margins Priority 96 · 10 threads

Capital & Balance Sheet Priority 95 · 5 threads

Strategy & Portfolio Priority 90 · 4 threads

Legal, Regulatory & Policy Priority 90 · 8 threads

Guidance & Outlook Priority 85 · 1 thread

Macro & Market Conditions Priority 69 · 2 threads

Management & Governance Priority 22 · 1 thread

Unclassified Priority 93 · 5 threads

Expected impact by metric

metricforward netforward grossrealized
operating_income+188.1%+266.6%-170.8%
revenue-13.9%+33.6%+420.3%
net_income-3.7%+3.7%+42.0%
assets-0.7%+0.8%—
liability-0.2%+0.5%—
cash-0.3%+0.5%-8.9%
margin——-1.4%